KBLB Reports $4.8M Capital Raise at Discounted Price, Addresses Going Concern

summarizeSummary

Kraig Biocraft Laboratories, Inc. disclosed the sale of 53.86 million shares for $4.82 million under its Standby Equity Purchase Agreement, with an additional $5.18 million remaining available. This capital raise, executed at a significant discount to market price, is critical for the company's operations given its 'going concern' status.

check_boxKey Events

• Updated Capital Raise Status

  Kraig Biocraft Laboratories, Inc. reported that it has sold a total of 53,857,821 shares of common stock under its Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd., generating aggregate gross proceeds of $4,824,033 as of April 30, 2026.

• Remaining Funding and Potential Dilution

  The company has $5,175,967 remaining available for sale under the $10 million SEPA. The total shares registered for resale by the selling stockholder, including commitment shares, amount to 207,787,193, representing a potential dilution of 18.78% of outstanding shares if fully issued.

• Recent Sales Pricing

  Recent sales between January 15, 2026, and March 30, 2026, involved 15,781,601 shares for $1,549,866, averaging approximately $0.0982 per share, which is significantly below the current market price of $0.14943.

• Going Concern Warning

  The company's financial statements include a 'going concern' qualification, highlighting the critical need for additional funding to sustain operations. Proceeds from the SEPA are allocated for working capital and general corporate purposes.

auto_awesomeAnalysis

This 424B3 filing provides a critical update on Kraig Biocraft Laboratories' ongoing capital raise through its Standby Equity Purchase Agreement (SEPA). The company has successfully raised $4.82 million by selling over 53 million shares, with an additional $5.18 million remaining under the $10 million agreement. While this capital infusion is vital for a company operating under a 'going concern' qualification, the shares were sold at a significant discount to the current market price, leading to substantial dilution for existing shareholders. The potential for further dilution from the remaining SEPA capacity and the total registered shares for resale (up to 18.78% of outstanding shares) creates a considerable overhang on the stock. Investors should monitor the company's use of proceeds and its ability to achieve profitability, especially given the ongoing operational progress in spider silk production.